Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ICML 2023
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
Want to know the key updates in MDS from ASH 2025?
🎧Listen to our podcast: https://ow.ly/ph2q50XJuO9
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
ICML 2023
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
Want to know the key updates in MDS from ASH 2025?
🎧Listen to our podcast: https://ow.ly/ph2q50XJuO9
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
